Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-15	0.5810 $	-0.50%	154,246
26-06-12	0.5839 $	-1.20%	127,588
26-06-11	0.5910 $	-0.17%	168,820
26-06-10	0.5920 $	-0.84%	198,288
26-06-09	0.5970 $	+2.40%	311,366

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 16:00:00 2026-06-15 EDT			5-day change	1st Jan Change
0.5810 ^USD	-0.50%		-0.34%	-47.18%

06-02	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
05-20	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	6.19M 5.33M 4.91M 4.6M 8.65M 585M 8.74M 58.03M 22.67M 286M 23.22M 22.73M 991M	P/E Ratio 2026 *	-	P/E Ratio 2027 *	-
Enterprise Value	6.19M 5.33M 4.91M 4.6M 8.65M 585M 8.74M 58.03M 22.67M 286M 23.22M 22.73M 991M	EV / Sales 2026 *	4.17x	EV / Sales 2027 *	2.38x
Free-Float	82.9%	Yield 2026 *	-	Yield 2027 *	-

06-02	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
05-20	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Evogene Ltd., Q1 2026 Earnings Call, May 20, 2026
05-20	Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing	RE
04-24	Evogene's Casterra unit eyes castor crop growth in Brazil	RE
04-02	Evogene reports receipt of Nasdaq minimum bid price notification	RE
04-02	Evogene Gets Nasdaq Minimum Bid Price Notification	MT
03-05	Evogene Ltd., Q4 2025 Earnings Call, Mar 05, 2026
03-05	Evogene Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-25	Evogene substantially completed divestment of non-core subsidiaries	RE
02-17	Evogene Ltd. and Queensland University of Technology Announce A Collaboration to Advance AI-Driven Cancer Therapeutics	CI
02-11	Evogene, Systasy and LMU University Hospital Munich announce a collaboration to develop therapies for inflammatory diseases	RE
02-11	Evogene Ltd. and LMU University Hospital Munich Announce Collaboration Aiming to Accelerate the Development of Novel Therapies for Hyperinflammatory Diseases Driven by Dysregulated Neutrophil Activity	CI

23-10-02	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
23-08-18	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
21-07-29	EVOGENE : Aegis Capital Starts Evogene at Buy	MT
20-12-01	EVOGENE : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

Evogene Ltd. Stock Nasdaq

Stocks

EVGN

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd.

Chart: Evogene Ltd.

Latest news : Evogene Ltd.

Last Transcript: Evogene Ltd.

Analysts' recommendations: Evogene Ltd.

Press Releases: Evogene Ltd.

News in other languages: Evogene Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Evogene Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

06-02	Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica	PR
05-20	Evogene : Q1 2026 Consolidated Financial Statements	PU
05-20	Evogene: Q1 Earnings Snapshot	AQ
05-20	Evogene Reports First Quarter 2026 Financial Results	PR
05-12	Evogene to Present at the 24th Schrödinger European User Group Meeting	PR

1 day	-0.50%
1 week	-0.34%
Current month	-17.59%
1 month	-20.68%
3 months	-27.14%
6 months	-44.43%
Current year	-47.18%

1 week	0.55	0.6
1 month	0.52	0.78
Current year	0.52	1.24
1 year	0.52	1.63
3 years	0.52	14.4
5 years	0.52	38.49
10 years	0.52	102.39

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	2004-11-30
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	2021-12-31

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	2010-06-02
Sarit Firon CHM	Chairman	60	2021-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD.	-0.50%	-0.34%	-	-	6.19M
LONZA GROUP AG	+1.39%	+1.19%	-11.60%	-11.70%	43.58B
REVOLUTION MEDICINES, INC.	+4.02%	+7.79%	+294.33%	+536.67%	34.03B
IQVIA HOLDINGS INC.	-1.69%	-2.89%	+13.70%	-17.71%	29.77B
BEONE MEDICINES AG	+1.41%	-0.96%	-0.53%	+33.41%	29.82B
CELLTRION, INC.	+1.16%	+9.79%	+14.27%	+22.28%	25.42B
ASCENDIS PHARMA A/S	+2.40%	+8.49%	-	-	13.87B
MEDPACE HOLDINGS, INC.	+0.03%	+2.10%	+56.75%	+111.91%	13.35B
EUROFINS SCIENTIFIC SE	+0.32%	-2.15%	+3.82%	+3.38%	12.85B
IONIS PHARMACEUTICALS, INC.	+0.93%	+0.57%	+107.81%	+77.40%	12.22B
Average	+0.94%	+1.88%	+59.82%	+94.46%	23.88B
Weighted average by Cap.	+1.24%	+1.86%	+61.62%	+105.80%

	2026 *	2027 *
Net sales	1.48M 1.28M 1.18M 1.1M 2.07M 140M 2.1M 13.92M 5.44M 68.68M 5.57M 5.45M 238M	2.6M 2.24M 2.06M 1.93M 3.63M 246M 3.67M 24.38M 9.52M 120M 9.76M 9.55M 416M
Net income	-16.69M -14.38M -13.24M -12.42M -23.33M -1.58B -23.56M -156M -61.13M -772M -62.62M -61.29M -2.67B	-13.92M -11.99M -11.04M -10.35M -19.45M -1.32B -19.65M -130M -50.97M -644M -52.22M -51.11M -2.23B
Net Debt	-	-